New Mirikizumab Efficacy Data in Crohn’s Disease
- Long-term data reveals sustained efficacy and safety of Mirikizumab in treating moderate to severe Crohn's disease and ulcerative colitis.
- Recent findings presented at the Crohn's and Colitis Congress (CCC) in San Francisco highlight the long-term benefits of Omvoh™ (mirikizumab) for patients with moderate to severe Crohn's disease.The...
- Notably, the study included patients with a history of prior biologic failure (43.8 percent), suggesting that mirikizumab may offer a viable option for those who have not responded...
Mirikizumab: A New Hope for Crohn’s Disease and Ulcerative Colitis Patients?
Table of Contents
- Mirikizumab: A New Hope for Crohn’s Disease and Ulcerative Colitis Patients?
- Mirikizumab: Your Questions Answered about This IBD Treatment
- What is Mirikizumab (omvoh™) and What Does it Treat?
- How Does Mirikizumab Work?
- What Were the Key Findings of the VIVID-2 Study?
- What Long-Term Efficacy Data Exists for Mirikizumab?
- What is the safety Profile of Mirikizumab?
- What Do Experts Say About Mirikizumab?
- Mirikizumab: Key Outcomes at 2 years
- Is Mirikizumab a Cure for Crohn’s Disease and Ulcerative Colitis?
Long-term data reveals sustained efficacy and safety of Mirikizumab in treating moderate to severe Crohn’s disease and ulcerative colitis.
omvoh™ (mirikizumab): A Breakthrough in IBD Treatment
Recent findings presented at the Crohn’s and Colitis Congress (CCC) in San Francisco highlight the long-term benefits of Omvoh™ (mirikizumab) for patients with moderate to severe Crohn’s disease.The VIVID-2 open-label extension study demonstrated that a meaningful proportion of patients achieved sustained clinical and endoscopic outcomes over two years of continuous treatment with mirikizumab.
Notably, the study included patients with a history of prior biologic failure (43.8 percent), suggesting that mirikizumab may offer a viable option for those who have not responded to other therapies.
Mirikizumab, an interleukin-23p19 antagonist, has emerged as a promising treatment for both Crohn’s disease and ulcerative colitis. it works by reducing inflammation in the gastrointestinal tract by targeting interleukin-23p19, a key protein involved in intestinal inflammation.
Omvoh (mirikizumab-mrkz) is an interleukin-23p19 antagonist indicated for the treatment of adult patients with moderate to severe ulcerative colitis or Crohn’s disease.
VIVID-2 Study: Key Findings on Mirikizumab
The VIVID-2 study provided compelling data on the long-term efficacy of mirikizumab. Among patients who achieved clinical remission after one year of treatment in VIVID-1,92.9 percent maintained remission at two years, as measured by the Crohn’s Disease Activity Index (CDAI).
Furthermore, 87.6 percent of patients who achieved an endoscopic response at one year in the VIVID-1 study maintained that response, defined as visible healing of the intestinal lining and a ≥50 percent reduction from baseline in the Simple Endoscopic Score for Crohn’s Disease (SES-CD).
In addition,78.6 percent of patients who were in endoscopic remission at one year in VIVID-1 maintained remission at two years,measured by a reduction of the SES-CD ≤4 and ≥2 points from baseline,with no individual variable exceeding a subscore of 1.
| Outcome | Patients Maintaining Outcome at 2 Years |
|---|---|
| Clinical Remission (CDAI) | 92.9% |
| Endoscopic Response (SES-CD) | 87.6% |
| Endoscopic Remission (SES-CD) | 78.6% |
additional Insights into Mirikizumab Treatment
The study also revealed that among patients who had not achieved clinical remission at one year, 60.8 percent achieved clinical remission during the second year. Similarly, 35.4 percent of patients who had not achieved endoscopic remission at one year achieved endoscopic remission during the second year of treatment with mirikizumab.
The long-term safety profile of mirikizumab in patients with moderate to severe Crohn’s disease was consistent with the known safety profile.During the second year of continuous treatment, 6.8 percent of patients with an endoscopic response at one year reported a serious adverse event,and 0.8 percent discontinued treatment due to an adverse event.
Mirikizumab-mrkz injection is used to treat moderate to severe active Crohn’s disease and ulcerative colitis. This medicine is available only with your doctor’s prescription.
Expert Opinion on Mirikizumab
According to experts, mirikizumab offers a valuable option for patients who have not responded to other therapies.
Many people who have Crohn’s disease have unsuccessfully tried available therapies or have experienced a loss of efficacy from their treatment.
These long-term results may give healthcare professionals confidence that mirikizumab can help their patients achieve and maintain long-term outcomes, including mucosal healing.
Mirikizumab: Your Questions Answered about This IBD Treatment
Mirikizumab (Omvoh™) is emerging as a potential game-changer in the treatment of moderate to severe Crohn’s disease and ulcerative colitis. This Q&A guide provides extensive data about mirikizumab, its efficacy, and what it could mean for patients seeking long-term relief.
What is Mirikizumab (omvoh™) and What Does it Treat?
Mirikizumab, marketed as omvoh™, is an interleukin-23p19 antagonist. It’s specifically designed to treat adult patients suffering from moderate to severe ulcerative colitis and Crohn’s disease. It’s available via prescription from your doctor.
How Does Mirikizumab Work?
Mirikizumab works by targeting interleukin-23p19, a key protein involved in intestinal inflammation. By blocking this protein,mirikizumab helps reduce inflammation in the gastrointestinal tract,alleviating symptoms of Crohn’s disease and ulcerative colitis.
What Were the Key Findings of the VIVID-2 Study?
The VIVID-2 open-label extension study demonstrated the long-term benefits of mirikizumab for patients with moderate to severe Crohn’s disease. Key findings include:
Sustained Clinical and Endoscopic Outcomes: The study showed a meaningful proportion of patients achieved sustained clinical and endoscopic outcomes over two years of continuous treatment with mirikizumab.
Efficacy in Patients with Prior Biologic Failure: The study included patients with a history of prior biologic failure (43.8 percent), suggesting mirikizumab may be effective for those who haven’t responded to other therapies.
What Long-Term Efficacy Data Exists for Mirikizumab?
The VIVID-2 study provided compelling data on the long-term efficacy of mirikizumab:
Clinical Remission: Among patients who achieved clinical remission after one year, 92.9% maintained remission at two years, as measured by the Crohn’s Disease Activity Index (CDAI).
Endoscopic Response: 87.6% of patients who achieved an endoscopic response at one year maintained that response at two years, defined as visible healing of the intestinal lining and a ≥50% reduction in the Simple Endoscopic Score for Crohn’s Disease (SES-CD).
Endoscopic Remission: 78.6% of patients who were in endoscopic remission at one year maintained remission at two years,measured by a reduction of the SES-CD ≤4 and ≥2 points from baseline.
Delayed Remission: Approximately 60.8% of patients who had not achieved clinical remission at one year,achieved clinical remission during the second year. Similarly, 35.4% of patients who had not achieved endoscopic remission at one year, achieved endoscopic remission during the second year.
What is the safety Profile of Mirikizumab?
The long-term safety profile of mirikizumab in patients with moderate to severe Crohn’s disease was consistent with its known safety profile. During the second year of continuous treatment, 6.8% of patients with an endoscopic response at one year reported a serious adverse event, and 0.8% discontinued treatment due to an adverse event.
What Do Experts Say About Mirikizumab?
Experts believe that mirikizumab offers a valuable option for patients who have not responded to other therapies. Many individuals with Crohn’s disease have unsuccessfully tried available treatments or have experienced a loss of efficacy from their treatment. Long-term results provide healthcare professionals confidence that mirikizumab can help patients achieve and maintain long-term outcomes, including mucosal healing.
Mirikizumab: Key Outcomes at 2 years
| Outcome | Patients Maintaining Outcome at 2 Years |
| :——————————- | :————————————– |
| Clinical Remission (CDAI) | 92.9% |
| Endoscopic Response (SES-CD) | 87.6% |
| Endoscopic Remission (SES-CD) | 78.6% |
Is Mirikizumab a Cure for Crohn’s Disease and Ulcerative Colitis?
Mirikizumab is a treatment,not a cure,for Crohn’s disease and ulcerative colitis. It helps manage the symptoms and reduce inflammation, but it does not eliminate the underlying disease.
Disclaimer: This article provides information about mirikizumab for educational purposes only and does not constitute medical advice. Consult with a healthcare professional for personalized guidance.